Etanercept
Tumor Necrosis Factor Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: enbrel, erelzi, etanercept (genetical recombination), etanercept-szzs, TNR 001, TNR-001
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Etanercept is a drug in the Tumor Necrosis Factor Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1998. Its mechanism of action is classified as Tumor Necrosis Factor Receptor Blocking Activity. DrugCentral lists 1 molecular target, including TNF. Recorded indications include Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis and Plaque psoriasis.
- Drug class: Tumor Necrosis Factor Blocker.
- Mechanism of action: Tumor Necrosis Factor Receptor Blocking Activity.
- Molecular targets: TNF (1 listed in DrugCentral).
- Indications: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Plaque psoriasis and Psoriasis with arthropathy and others.
- ATC code: L04AB01 (Tumor necrosis factor alpha (TNF-alpha) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Ankylosing spondylitis
- Juvenile idiopathic arthritis
- Nonradiographic axial spondyloarthritis
- Plaque psoriasis
- Psoriasis with arthropathy
- Rheumatoid arthritis
Contraindications (1)
- Sepsis
Mechanism & targets
| Mechanism of action (MoA) | Tumor Necrosis Factor Receptor Blocking Activity |
|---|---|
| Established pharmacologic class | Tumor Necrosis Factor Blocker |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Tumor necrosis factor | TNF | inhibitor | — |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2005-01-19 | PMDA | — | WYETH LEDERLE JAPAN, WYETH | |
| 2000-02-03 | EMA | — | — | |
| 1998-11-02 | FDA | — | IMMUNEX |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AB01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Injection site erythema | 52083.3 |
| Injection site pain | 50456.8 |
| Injection site pruritus | 28648.1 |
| Injection site swelling | 27080.1 |
| Injection site reaction | 19752.6 |
| Injection site bruising | 15965.1 |
| Injection site warmth | 15328.8 |
| Drug ineffective | 12968.4 |
| Arthralgia | 10255.0 |
| Injection site rash | 8277.6 |
| Injection site haemorrhage | 8233.1 |
| Wrong technique in product usage process | 7400.7 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 185243-69-0 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Etanercept used for?
DrugCentral lists the following indications for Etanercept: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Plaque psoriasis, Psoriasis with arthropathy and Rheumatoid arthritis.
How does Etanercept work?
Etanercept is classified as Tumor Necrosis Factor Receptor Blocking Activity; its molecular targets in DrugCentral include TNF (inhibitor).
When was Etanercept first approved?
Etanercept was first approved by the FDA in 1998.
What drug class does Etanercept belong to?
Etanercept is in the Tumor Necrosis Factor Blocker class.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4978 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201572 — compound record and bioactivity
- DrugBank DB00005 — drug record
- FDA UNII OP401G7OJC — substance identity
- DailyMed: FDA labels for Etanercept — current prescribing information (label search)
- UniProt P01375 (TNF) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.